Clinical Trial Update: Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update notes the completion of a Phase 2 study evaluating idarubicin-based combined modality therapy for primary central nervous system lymp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Lymphoma

Drugs mentioned

• Idarubicin (idarubicin)

Snippet

Sponsor: Trans Tasman Radiation Oncology Group | Conditions: Primary Central Nervous System Lymphoma | Phase 2 | Status: COMPLETED